ECDC rapid risk assessment outlines actions to reduce the spread of the mcr-1 gene

June 17, 2016, European Centre for Disease Prevention and Control (ECDC)
The recently recognized global distribution of the mcr-1 gene poses a substantial public health risk to the EU/EEA. The gene is widespread in several continents and has been detected in bacteria isolated from multiple different sources such as food-producing animals, food, the environment and humans. Credit: Skov RL, Monnet DL. Plasmid-mediated colisting resistance (mcr-1 gene): three months later, the story unfolds. Eurosurveillance, 2016;21(9). Updated with the latest available data on 2 June 2016 by ECDC.

The recently recognised global distribution of the mcr-1 gene poses a substantial public health risk to the EU/EEA. The gene is widespread in several continents and has been detected in bacteria isolated from multiple different sources such as food-producing animals, food, the environment and humans.

This new mechanism of to colistin is of exceptional concern because it further limits treatment options in patients with infections caused by multidrug-resistant (MDR) Gram-negative bacteria, and also because it is a highly mobile type of drug resistance (the gene is on a plasmid) that can spread more easily between bacteria.

MDR Gram-negative bacteria, including carbapenem-resistant Enterobacteriaceae strains that acquire the mcr-1 gene, remain susceptible to only a few antimicrobial agents, which means that infections caused by these strains are very difficult to treat and result in excess mortality. As the development of new antimicrobials is unlikely to provide a solution anytime soon, it is crucial to take measures to control the spread of mcr-1 and thus protect the activity of colistin.

Although there are still major information gaps, relating to the current prevalence of colistin resistance in human clinical isolates in the EU/EEA, as well as to the historical and current prevalence of colistin resistance due to the mcr-1 gene, the issue of further spread of mcr-1 needs to be taken seriously and be carefully monitored by EU/EEA countries.

Andrea Ammon, ECDC Acting Director, said: "the spread of the mcr-1 gene represents another step towards pandrug resistance and infections that would be very difficult, if not impossible, to treat. Further spread would increase the morbidity and mortality in patients undergoing advanced medical procedures, thus having a profound effect on the practice of medicine."

In its rapid risk assessment, ECDC outlines a number of actions that need to be considered to reduce identified risks of mcr-1 spread. These include improved laboratory methods for colistin resistance testing and mcr-1 detection, improved surveillance, options for appropriate clinical management, and actions to prevent transmission in healthcare settings as well as in the community.

Explore further: First discovery in United States of colistin resistance in a human E. coli infection

Related Stories

First discovery in United States of colistin resistance in a human E. coli infection

May 26, 2016
The Multidrug Resistant Organism Repository and Surveillance Network (MRSN) at the Walter Reed Army Institute of Research (WRAIR) characterized a transferrable gene for colistin resistance in the United States that may herald ...

US to establish lab network for combating 'superbugs'

June 1, 2016
US authorities said Tuesday they are establishing a network of labs that can respond quickly to antibiotic-resistant "superbugs," following America's first human case of a dangerous strain of E. coli.

New gene that makes common bacteria resistant to last-line antibiotic found in animals and patients in China

November 19, 2015
A new gene (mcr-1) that enables bacteria to be highly resistant to polymyxins, the last line of antibiotic defence we have left, is widespread in Enterobacteriaceae taken from pigs and patients in south China, including strains ...

What you need to know about E. coli

January 8, 2016
A new drug-resistant superbug gene has been discovered in meat sold in Ontario.

New front opens in war on superbugs: experts

April 11, 2016
A newly-discovered antibiotic-resistant gene is threatening to open a new front in the war against superbugs by rendering a last-resort drug impotent, experts warn.

New technology traces resistance gene quickly

December 8, 2015
A new resistance gene has been found in coli bacteria among pigs, broiler meat and humans in China. Bacteria with the same resistance gene have now also been found in Denmark, according to a new Danish study. The National ...

Recommended for you

A new approach to developing a vaccine against vivax malaria

September 21, 2018
A novel study reports an innovative approach for developing a vaccine against Plasmodium vivax, the most prevalent human malaria parasite outside sub-Saharan Africa. The study led by Hernando A. del Portillo and Carmen Fernandez-Becerra, ...

Pre-clinical success for a universal flu vaccine offers hope for third generation approach

September 21, 2018
Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Communications.

Researchers define possible molecular pathway for neurodegeneration in prion diseases

September 21, 2018
A new study has shed light on the mechanisms underlying the progression of prion diseases and identified a potential target for treatment.

Fighting a deadly parasite: Scientists devise a method to store Cryptosporidium, aiding vaccine research efforts

September 21, 2018
In May, just before one of the hottest summers on record, the U.S. Centers for Disease Control and Prevention issued a warning about diseases lurking in recreational water facilities like swimming pools and water playgrounds. ...

Scientists make significant discovery in the fight against drug-resistant tuberculosis

September 20, 2018
A team of scientists have identified a naturally occurring antibiotic that may help in the fight against drug-resistant Tuberculosis.

Anti-cancer drugs may hold key to overcoming antimalarial drug resistance

September 20, 2018
Scientists have found a way to boost the efficacy of the world's most powerful antimalarial drug with the help of chemotherapy medicines, according to new research published in the journal Nature Communications.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.